FATE Fate Therapeutics Inc.

24.16
-0.68  -3%
Previous Close 24.84
Open 24.94
Price To Book 6.81
Market Cap 1,826,320,574
Shares 75,592,739
Volume 662,152
Short Ratio
Av. Daily Volume 1,084,476
Stock charts supplied by TradingView

NewsSee all news

  1. Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

    FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies Published Preclinical Data Demonstrate iPSC-derived NK Cells Engineered with

  2. Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

    FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and

  3. Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

    FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In Vivo in Preclinical

  4. Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

    No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs

  5. Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data released at SITC November 10, 2017.
FATE-NK100
Acute myelogenous leukemia (AML)
Phase 2 data due 2020.
ProTmune - PROTECT
Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT)
Phase 1 trial initiated February 2018.
NK100 - DIMENSION
Solid tumors
Phase 1 dosing commenced February 2019. No dose-limiting toxicities related SAEs - noted December 7, 2019.
FT500
Soild tumors
Phase 1 trial ongoing. Noted complete neutrophil recovery observed in first AML patient - December 7, 2019.
FT516
Acute Myelogenous Leukemia

Latest News

  1. Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

    FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies Published Preclinical Data Demonstrate iPSC-derived NK Cells Engineered with

  2. Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

    FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and

  3. Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

    FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In Vivo in Preclinical

  4. Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

    No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs

  5. Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

  6. Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

  7. Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting

    FT596 Selected by ASH for Feature at "CAR-T and Beyond" Press Conference on December 7 Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for

  8. Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

    First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with Rituximab Received FDA Clearance of IND Application for FT596, an Off-the-Shelf,

  9. Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

  10. Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

    SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

  11. Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  12. Fate Therapeutics Announces Pricing of Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  13. Fate Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  14. Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune